In:
International Journal of Cancer, Wiley, Vol. 140, No. 1 ( 2017-01), p. 103-108
Abstract:
What's new? Intratumor heterogeneity (ITH) in non‐small cell lung cancer (NSCLC) may account for resistance during targeted treatment. Identifying ITH could help make effective treatment decisions, but ITH studies have so far been hampered by confounding factors. To reduce the interference of interpatient heterogeneity and passenger mutations, the authors recruited NSCLC patients with TP53 mutations and selected potential driver mutations. They identified extensive ITH of driver mutations in all NSCLC tumors and demonstrated the late molecular acquisition of TP53 mutation during tumor progression in most patients. The data highlight the clinical potential of limiting the impact of ITH for NSCLC targeted treatment.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8